A phase I clinical trial of GM-CSF [granulocyte macrophage colony stimulating factors] administration as a biological adjuvant in clinically-staged, resectable pancreatic adenocarcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Granulocyte-macrophage colony-stimulating factors (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 11 Jun 2018 Biomarkers information updated
- 02 Jul 2013 Planned end date changed from 1 Dec 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 14 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.